ERBB2 and carcinoma: The two variants (NE-like and stroma-rich) do not exhibit HER2 overexpression—in our cohort, all neuroendocrine-like cases (n = 6) are 0, and of the two stroma-rich cases one is 0 and one is “ultra-low.” These data highlight that HER2 status may be related to the tumor’s molecular profile: luminal carcinomas express HER2 significantly more often compared to basal carcinomas (p < 0.001).